🔊CEOInterviews

Udit Batra on revenue guidance

From Waters Corp ($WAT) Q1 2026 Earnings Call · · Castify Earnings Call

“We are raising our full-year 2026 organic constant currency revenue guidance to 6.5% to 8% reflecting our strong first quarter performance and embedding $15 million of expected revenue synergies from cross-selling of aspect.”

Udit Batra
President, Chief Executive Officer & Director, Waters Corp
Policy Impact revenue guidancesynergiesgrowth outlook

On , Udit Batra, President, Chief Executive Officer & Director at Waters Corp, spoke about revenue guidance during Waters Corp ($WAT) Q1 2026 Earnings Call on Castify Earnings Call.

Waters Corp ($WAT) Q1 2026 Earnings Call
Watch on YouTube at 19:51
Waters Corp ($WAT) Q1 2026 Earnings Call
Castify Earnings Call
Watch on YouTube at 19:51
Good morning welcome to the Waters Corporation first quarter 2026 financial results conference call all participants will be in ...
Udit Batra

About Udit Batra

President, Chief Executive Officer & Director · Waters Corp

Udit Batra, President and CEO of Waters, has been leading the company through its combination with BD’s biosciences and diagnostic solutions business, which closed around the end of the first quarter of 2026. On the Q1 2026 earnings call, Batra described the quarter as “excellent” and said the combined company achieved double-digit organic growth in legacy businesses and better-than-expected revenue from the acquired businesses. He noted that Waters intends to begin manufacturing key products in China for China starting in the third quarter of 2026, and that an initial review of 1,600 US diagnostic solutions contracts identified approximately 700 out of compliance, representing a “double-digit million dollar shortfall annually.” Batra raised full-year 2026 organic constant currency revenue growth guidance to 6.5% to 8% and adjusted EPS guidance to $14.40–$14.60. In prior earnings calls, Batra discussed the company’s strategy for the BD acquisition, including expectations for $345 million in adjusted EBITDA synergies by year five. He also commented on the instrument replacement cycle, stating it is “going really well” and provides a runway into 2027, with reshoring expected to bridge into the next cycle. Batra highlighted the potential for a proposed FDA biosimilar framework to increase demand for analytical instruments, and noted that Waters is introducing cloud-native features using AI and machine learning for QA/QC labs. He raised full-year 2025 guidance twice during the year, citing strong performance in segments such as battery testing and high-resolution mass spectrometry in China.

Profile compiled from Udit Batra's verified public interviews and appearances. See all quotes & transcripts →

More from Udit Batra Waters Corporation (WAT) Full Transcript Explore All Executives